alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding

J K Stoller; L S Aboussouan

doi:10.1136/thx.2003.006544

alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding

Thorax. 2004 Aug;59(8):708-12. doi: 10.1136/thx.2003.006544.

Authors

J K Stoller¹, L S Aboussouan

Affiliation

¹ Division of Medicine, Section of Respiratory Therapy, Cleveland Clinic Lerner School of Medicine, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. stollej@ccf.org

Abstract

The biochemical and clinical efficacy of intravenous augmentation therapy in alpha(1)-antitrypsin deficiency is reviewed, adverse events experienced with this treatment are considered, and its cost effectiveness is discussed.

Publication types

Review

MeSH terms

Cost-Benefit Analysis
Forced Expiratory Volume / physiology
Humans
Infusions, Intravenous
Treatment Outcome
alpha 1-Antitrypsin / administration & dosage*
alpha 1-Antitrypsin Deficiency / drug therapy*
alpha 1-Antitrypsin Deficiency / economics
alpha 1-Antitrypsin Deficiency / physiopathology

Substances

alpha 1-Antitrypsin